Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$29.20 +1.2%	$30.07	$24.40 ▼ $36.45	$4.76B	0.44	1.73 million shs	1.66 million shs
IONS Ionis Pharmaceuticals	$42.77 +1.8%	$36.92	$23.95 ▼ $52.34	$6.68B	0.23	1.62 million shs	1.38 million shs
MDGL Madrigal Pharmaceuticals	$344.97 +10.9%	$290.11	$200.63 ▼ $377.46	$6.91B	-1.05	361,722 shs	1.30 million shs
UTHR United Therapeutics	$298.16 +1.7%	$300.81	$266.98 ▼ $417.82	$13.23B	0.53	443,603 shs	324,808 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	+1.21%	-2.60%	-0.75%	+7.94%	+18.70%
IONS Ionis Pharmaceuticals	+1.83%	-0.14%	+21.37%	+50.60%	-14.19%
MDGL Madrigal Pharmaceuticals	+10.87%	+11.79%	+21.02%	+14.36%	+26.03%
UTHR United Therapeutics	+1.68%	-0.80%	+3.33%	+4.72%	-9.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALKS Alkermes	4.7914 of 5 stars	4.4	1.0	4.2	3.3	2.5	1.9
IONS Ionis Pharmaceuticals	4.5363 of 5 stars	4.4	2.0	3.0	2.6	3.3	0.6
MDGL Madrigal Pharmaceuticals	3.7534 of 5 stars	2.4	1.0	4.6	2.8	3.3	0.6
UTHR United Therapeutics	4.988 of 5 stars	4.3	5.0	4.6	3.5	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.83	Moderate Buy	$40.92	40.13% Upside
IONS Ionis Pharmaceuticals	2.76	Moderate Buy	$57.13	33.58% Upside
MDGL Madrigal Pharmaceuticals	2.89	Moderate Buy	$420.63	21.93% Upside
UTHR United Therapeutics	2.69	Moderate Buy	$383.08	28.48% Upside

Current Analyst Ratings Breakdown

Latest UTHR, IONS, MDGL, and ALKS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	ALKS Alkermes	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$43.00
7/10/2025	UTHR United Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$348.00 ➝ $328.00
7/8/2025	UTHR United Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$350.00 ➝ $330.00
7/1/2025	IONS Ionis Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$51.00 ➝ $57.00
6/30/2025	UTHR United Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$410.00 ➝ $385.00
6/26/2025	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/17/2025	ALKS Alkermes	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$33.00 ➝ $42.00
6/12/2025	IONS Ionis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$45.00 ➝ $48.00
6/11/2025	UTHR United Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$321.00 ➝ $315.00
6/2/2025	UTHR United Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$405.00
5/28/2025	ALKS Alkermes	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral ➝ Buy	$45.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.56B	3.09	$2.68 per share	10.88	$9.05 per share	3.23
IONS Ionis Pharmaceuticals	$705M	9.66	N/A	N/A	$3.73 per share	11.47
MDGL Madrigal Pharmaceuticals	$180.13M	42.52	N/A	N/A	$34.59 per share	9.97
UTHR United Therapeutics	$2.88B	4.67	$28.86 per share	10.33	$144.34 per share	2.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$367.07M	$2.09	13.97	21.31	1.79	23.30%	27.52%	17.98%	7/23/2025 (Estimated)
IONS Ionis Pharmaceuticals	-$453.90M	-$2.99	N/A	N/A	N/A	-63.65%	-91.85%	-15.77%	7/30/2025 (Estimated)
MDGL Madrigal Pharmaceuticals	-$465.89M	-$18.05	N/A	N/A	N/A	-123.38%	-50.54%	-37.19%	8/6/2025 (Estimated)
UTHR United Therapeutics	$1.20B	$25.06	11.90	10.85	6.41	40.44%	19.33%	16.73%	7/30/2025 (Estimated)

Latest UTHR, IONS, MDGL, and ALKS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	IONS Ionis Pharmaceuticals	$0.19	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	MDGL Madrigal Pharmaceuticals	-$3.64	N/A	N/A	N/A	$158.94 million	N/A
7/30/2025	Q2 2025	UTHR United Therapeutics	$6.89	N/A	N/A	N/A	$802.13 million	N/A
7/23/2025	Q2 2025	ALKS Alkermes	$0.42	N/A	N/A	N/A	$343.20 million	N/A
5/1/2025	Q1 2025	ALKS Alkermes	$0.32	$0.13	-$0.19	$0.13	$307.53 million	$306.51 million
5/1/2025	Q1 2025	MDGL Madrigal Pharmaceuticals	-$3.62	-$3.32	+$0.30	-$3.32	$112.79 million	$137.25 million
4/30/2025	Q1 2025	IONS Ionis Pharmaceuticals	-$1.07	-$0.93	+$0.14	-$0.93	$144.31 million	$132.00 million
4/30/2025	Q1 2025	UTHR United Therapeutics	$6.29	$6.63	+$0.34	$6.63	$726.82 million	$794.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	N/A	3.33	2.92
IONS Ionis Pharmaceuticals	2.63	9.66	9.62
MDGL Madrigal Pharmaceuticals	0.17	5.91	5.58
UTHR United Therapeutics	N/A	5.46	5.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
IONS Ionis Pharmaceuticals	93.86%
MDGL Madrigal Pharmaceuticals	98.50%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.40%
IONS Ionis Pharmaceuticals	2.60%
MDGL Madrigal Pharmaceuticals	21.50%
UTHR United Therapeutics	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	1,800	164.90 million	157.65 million	Optionable
IONS Ionis Pharmaceuticals	1,069	159.16 million	155.02 million	Optionable
MDGL Madrigal Pharmaceuticals	90	22.20 million	17.43 million	Optionable
UTHR United Therapeutics	1,305	45.11 million	40.46 million	Optionable

UTHR, IONS, MDGL, and ALKS Headlines

Recent News About These Companies

United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025

July 16 at 7:00 AM | businesswire.com

Envestnet Asset Management Inc. Increases Stake in United Therapeutics Corporation (NASDAQ:UTHR)

July 16 at 3:43 AM | marketbeat.com

Unpacking Q1 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) In The Context Of Other Therapeutics Stocks

July 15 at 8:37 AM | finance.yahoo.com

MQS Management LLC Purchases New Position in United Therapeutics Corporation (NASDAQ:UTHR)

July 15 at 5:38 AM | marketbeat.com

United Therapeutics Corporation (NASDAQ:UTHR) Shares Sold by M&T Bank Corp

July 15 at 4:27 AM | marketbeat.com

Paul A. Mahon Sells 11,000 Shares of United Therapeutics Corporation (NASDAQ:UTHR) Stock

July 14 at 7:16 PM | marketbeat.com

6,585 Shares in United Therapeutics Corporation (NASDAQ:UTHR) Bought by Aurora Investment Counsel

July 14 at 6:41 AM | marketbeat.com

Emerald Advisers LLC Sells 1,061 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

July 14 at 5:41 AM | marketbeat.com

Morgan Stanley Cuts United Therapeutics (NASDAQ:UTHR) Price Target to $328.00

July 13, 2025 | americanbankingnews.com

Nisa Investment Advisors LLC Sells 4,544 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

July 12, 2025 | marketbeat.com

United Therapeutics’ DeciPHer-ILD Study: A New Frontier in Pulmonary Hypertension Research

July 11, 2025 | tipranks.com

Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term

July 11, 2025 | zacks.com

Weil Company Inc. Buys 3,298 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

July 11, 2025 | marketbeat.com

1,822 Shares in United Therapeutics Corporation (NASDAQ:UTHR) Acquired by Rehmann Capital Advisory Group

July 11, 2025 | marketbeat.com

UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR)

July 10, 2025 | insidermonkey.com

J.P. Morgan Sticks to Their Buy Rating for United Therapeutics (UTHR)

July 10, 2025 | theglobeandmail.com

Morgan Stanley Has Lowered Expectations for United Therapeutics (NASDAQ:UTHR) Stock Price

July 10, 2025 | marketbeat.com

United Therapeutics’ Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis: Key Insights for Investors

July 9, 2025 | tipranks.com

United Therapeutics Corporation (NASDAQ:UTHR) Shares Bought by TD Private Client Wealth LLC

July 9, 2025 | marketbeat.com

World Investment Advisors Has $718,000 Stake in United Therapeutics Corporation (NASDAQ:UTHR)

July 9, 2025 | marketbeat.com

Teacher Retirement System of Texas Sells 1,343 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

July 9, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst
By Thomas Hughes | June 26, 2025
View Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst
2 Under the Radar Space & Defense Stocks With Huge Potential
By Leo Miller | July 1, 2025
View 2 Under the Radar Space & Defense Stocks With Huge Potential
3 Stocks to Buy Ahead of the Upcoming Earnings Season
By Chris Markoch | July 11, 2025
View 3 Stocks to Buy Ahead of the Upcoming Earnings Season
Rigetti Computing: Cantor's Bullish Call May Be Just the Start
By Jeffrey Neal Johnson | July 3, 2025
View Rigetti Computing: Cantor's Bullish Call May Be Just the Start

UTHR, IONS, MDGL, and ALKS Company Descriptions

Alkermes NASDAQ:ALKS

$29.20 +0.35 (+1.21%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$29.19 -0.01 (-0.03%)

As of 07/16/2025 07:34 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Ionis Pharmaceuticals NASDAQ:IONS

$42.77 +0.77 (+1.83%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$41.30 -1.47 (-3.44%)

As of 07/16/2025 06:35 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Madrigal Pharmaceuticals NASDAQ:MDGL

$344.97 +33.83 (+10.87%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$342.38 -2.60 (-0.75%)

As of 07/16/2025 07:59 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

United Therapeutics NASDAQ:UTHR

$298.16 +4.92 (+1.68%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$298.12 -0.04 (-0.01%)

As of 07/16/2025 06:46 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time